Schedule Lag
Definition
The delay between first identification of an NPS in forensic seizures and its formal addition to a controlled substances schedule. In India, this typically takes 12-36 months via gazette notification. During the lag, the compound can be sold without NDPS Act liability, creating a window of legal commercial availability for pharmacologically dangerous compounds.
- Definition
- Delay between NPS identification and formal scheduling
- Typical duration in India
- 12 to 36 months
- Mechanism
- Gazette notification
- Effect
- Legal commercial availability window
Common questions
Why does schedule lag favour synthetic cathinones and similar NPS?+
Manufacturers can tweak a molecule's structure just enough to create a new, technically unscheduled analogue, so by the time one variant is formally controlled a replacement compound may already be circulating, keeping the substance ahead of enforcement.
How do laboratories cope with a compound that has no legal status yet?+
They still test and report the compound's identity and pharmacological class for intelligence and public-health purposes, even though no NDPS Act charge can attach until it is formally scheduled.
Related terms
- Alpha-PVP (Alpha-Pyrrolidinopentiophenone)
- The MDPV successor ('flakka') dominant in Florida 2014-2016; associated with excited delirium presentations and multiple fatalities. Identified in over 60 deaths in...
- Cathinone
- The natural beta-ketoamphetamine alkaloid from Catha edulis (khat) plant; the parent scaffold for the synthetic cathinone NPS class. The ketone group at...
- EMCDDA Early Warning System
- The EU mechanism under Council Decision 2005/387/JHA by which national focal points (forensic labs, clinical sites) report new NPS to the EMCDDA...
- Federal Analogue Act (FAA)
- 21 USC 813; a provision of the US Controlled Substances Act declaring substances 'substantially similar' in structure or pharmacology to Schedule I...
- Isotonitazene (ISO)
- A benzimidazole-class novel synthetic opioid (nitazene family) estimated at ~500x the potency of morphine at the mu-opioid receptor. First identified in European...
- MDPV (Methylenedioxypyrovalerone)
- An alpha-pyrrolidinyl cathinone acting primarily as a dopamine/noradrenaline reuptake inhibitor. Central to the US 'bath salts' crisis 2011-2012; substantially more potent and...
- Mephedrone (4-MMC)
- 4-Methylmethcathinone; the dominant first-wave synthetic cathinone, active as a mixed monoamine releaser/reuptake inhibitor. Class B UK since April 2010; Schedule I US...
- Novel Psychoactive Substance (NPS)
- A substance designed to mimic the effects of a controlled drug while falling outside the definition of any currently scheduled substance; identified...
- Psychoactive Substances Act 2016 (UK)
- UK catch-all legislation prohibiting supply, distribution, import, and export of any substance with psychoactive effects on the CNS, with exemptions for alcohol,...